Item request has been placed!
×
Item request cannot be made.
×
Processing Request
Abbott cancer drug vying for FDA approval.
Item request has been placed!
×
Item request cannot be made.
×
Processing Request
- Author(s): Chase, Brett
- Source:
Crain's Chicago Business. 9/5/2005, Vol. 28 Issue 36, p4-4. 1/3p.
- Subject Terms:
- Additional Information
- Subject Terms:
- Subject Terms:
- Abstract:
The article reports that shares of Abbott Laboratories Inc. may get a much-needed boost if the drugmaker wins over a panel of doctors on what Abbott believes could be a breakthrough treatment for prostate cancer. The new treatment, a pill called Xinlay, could eventually add $2 billion a year to Abbott's sales. In early tests, Xinlay failed to meet Abbott's own goals for effectiveness. John Leonard, Abbott's vice-president of medical and scientific affairs, says, measuring success was difficult because there has been little research done in this area.
No Comments.